NUCB1 and myeloid sarcoma: This would be in line with other evidence that POMS patients exhibit less physical disability in the first-decade post-onset and have longer time to disease progression in spite of having increased inflammatory activity.32 Finally, protein NUCB1 has never been described in MS, but interestingly, it has been associated with primary neurodegenerative disorders.33 However, as this protein was not confirmed significantly (only as a trend) in our independent validation samples, further studies are needed to determine whether there is a role of this protein in POMS.